Business Wire - January 18, 2012
-- Viread Now Available in an Oral Powder and Three
Lower-Strength Tablets --
FOSTER CITY, Calif. - Gilead Sciences, Inc.
(Nasdaq:GILD) announced today that the U.S. Food and Drug
Administration (FDA) has approved Viread(R) (tenofovir disoproxil
fumarate) in combination with other antiretroviral agents for the
treatment of HIV-1 infection in pediatric patients ages 2-12. The
FDA approved a supplemental New Drug Application (sNDA) for three
lower-strength once-daily tablets of Viread in doses of 150 mg,
200 mg and 250 mg for children ages 6-12. The agency also
approved a New Drug Application (NDA) for an oral powder
formulation of Viread for children ages 2-5. The active
ingredient in Viread, tenofovir disoproxil fumarate, is currently
the most-prescribed molecule for adults receiving HIV therapy in
the United States.